A Future European Scientific Dialogue Regulatory Framework: Connecting the Dots

Area of Science:

• Regulatory Science
• Pharmaceutical Policy
• Drug Development

Background:

• The European Union (EU) regulatory framework offers valuable Scientific Advice (SA) options for drug development.
• Increasing scientific complexity and global competition present challenges in navigating the SA landscape.
• These challenges stem from the framework's technicalities and evolving therapeutic development.

Purpose of the Study:

• To provide an overview of the challenges in the EU's Scientific Advice (SA) framework.
• To propose consolidation and optimization of existing SA options for an integrated process.
• To inform discussions on the future of Scientific Dialogue and potential legislative changes.

Main Methods:

• Analysis of the current EU Scientific Advice (SA) framework and its challenges.
• Incorporation of ongoing dialogues involving the European Medicines Agency (EMA) and the European Medicines Regulatory Network (EMRN).
• Inclusion of the European Federation of Pharmaceutical Industries' (EFPIA) perspective on evolving SA.

Main Results:

• Identification of key areas for improvement: enhanced orientation, simplified parallel interactions, competitive timelines, stakeholder harmonization, improved horizon scanning, and institutional memory.
• A proposal for an integrated and easy-to-navigate SA process.
• Contribution to the ongoing discussion on the future of Scientific Dialogue.

Conclusions:

• The EU SA framework requires evolution to provide effective Scientific Dialogue throughout the medicine lifecycle.
• Optimizing the SA process is crucial for addressing current challenges in drug development.
• Proposed improvements can inform legislative changes and practical implementation for future drug development.